289891-95-8Relevant academic research and scientific papers
BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS
-
, (2016/07/05)
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as "BHBA compou
A transition-metal-free synthesis of fluorinated naphthols
Hammann, Jeffrey M.,Unzner, Teresa A.,Magauer, Thomas
, p. 6733 - 6738 (2014/06/09)
Herein, we describe a transition-metal-free protocol for the conversion of simple 2-allyl-3-(trifluoromethyl)phenols into substituted 5-fluoronaphthalen-1- ols. The key events of this reaction include the selective activation of two C-F bonds and formatio
Discovery of novel and potent retinoic acid receptor α agonists: Syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives
Yoshimura, Hiroyuki,Kikuchi, Kouichi,Hibi, Shigeki,Tagami, Katsuya,Satoh, Takashi,Yamauchi, Toshihiko,Ishibahi, Akira,Tai, Kenji,Hida, Takayuki,Tokuhara, Naoki,Nagai, Mitsuo
, p. 2929 - 2937 (2007/10/03)
In the course of our studies on retinoic acid receptor (RAR) agonists, we have designed and synthesized a series of benzofuran and benzothiophene derivatives. Some of these compounds (1a,b,e,f,j) markedly inhibited LPS- induced B-lymphocyte proliferation and exerted RARα selectivity. One of them, 4-[5-(4,7-dimethylbenzofuran-2-yl)pyrrol-2-yl]benzoic acid (1b), when orally administered significantly inhibited mouse antibody production and delayed type hypersensitivity (DTH) responses from a dose of 0.1 mg/kg.
